Focus: Chiesi is a specialty pharmaceutical company headquartered in Brazil with a focused portfolio in rare diseases and orphan drugs, including small molecules and biologics. The company generates 43% of revenue from its flagship product REVCOVI.
Profile data last refreshed 9h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Chiesi to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship rare disease biologic generating 43% of company revenue; cornerstone of commercial strategy.
Help build intelligence for Chiesi
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Chiesi's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue driver; JAK/STAT leptin receptor agonist addressing metabolic complications in rare lipodystrophy.
Peak-stage small molecule with 17+ years of patent protection; targets rare lipid disorder.
Somatostatin receptor agonist for neuroendocrine conditions; 16+ years of exclusivity.
Iron chelator for transfusion-dependent anemias; 14+ years of patent life.
Pegylated alpha-galactosidase A for rare lysosomal storage disease; early-stage growth asset.
Aminoglycoside inhaled antibiotic for CF chronic Pseudomonas aeruginosa infection.
Generic calcium channel blocker; post-LOE product with minimal revenue contribution.
Duplicate generic entry; post-LOE calendar product with minimal commercial focus.
9 discontinued, 18 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo+4 more products